All the news Showing 10 of 46 articles from: Previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study Liz Highleyman / 27 November 2013 An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response (SVR12) in 85% of Japanese patients with hepatitis C virus subtype 1b, according to ... Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows Liz Highleyman / 13 November 2013 At least 95% of newly treated people with genotype 1 hepatitis C and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to ... BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks Keith Alcorn / 06 November 2013 A combination of three direct-acting antivirals developed by Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson of the University of Colorado ... Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial Liz Highleyman / 06 November 2013 A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response (SVR12) in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course ... AbbVie's two-drug, interferon-free combination cures genotype 1b hepatitis C infection in 95% Keith Alcorn / 05 November 2013 A two-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virologic response in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need ... Two new hepatitis C drugs recommended for US approval Keith Alcorn / 02 November 2013 Two new direct acting antiviral agents for the treatment of hepatitis C have been unanimously recommended for approval by expert advisory panels in the United States. Full marketing approval from the US ... Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection Liz Highleyman / 22 October 2013 The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a ... Interferon-free simeprevir + sofosbuvir suppresses hepatitis C with or without ribavirin Liz Highleyman / 17 June 2013 An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment sustained response for most prior null responders with genotype 1 hepatitis C in ... Boceprevir benefits null, partial responders to prior HCV therapy with peginterferon/ribavirin Healio Hepatology / 12 June 2013 Simeprevir boosts response to interferon-based hepatitis C therapy for prior relapsers Liz Highleyman / 03 June 2013 Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after three months, according to ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive